DDInter1147 DDInter1602
Meningococcal group C polysaccharide is group-specific polysaccharide antigens extracted and purified from *Neisseria meningitidis* serogroup C. *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C.
Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease.[L39885,L44191,L44231] Risankizumab is being investigated for atopic dermatitis.
Risankizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Risankizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Omacetaxine mepesuccinate
Risankizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Risankizumab {u} may lead to a major life threatening interaction when taken with {v} Smallpox (Vaccinia) Vaccine, Live
Risankizumab {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Risankizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Risankizumab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Risankizumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Risankizumab may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Risankizumab may lead to a major life threatening interaction when taken with Upadacitinib